Zim Laboratories (NSE:ZIMLAB) Long-Term Debt: ₹416 Mil (As of Mar. 2026)


NSE:ZIMLAB Zim Laboratories Ltd NSE:ZIMLAB
80 GF Score
Price ₹122.50
GF Value ₹102.83
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Zim Laboratories Long-Term Debt?

Zim Laboratories NSE:ZIMLAB -1.21% 80 Long-Term Debt is ₹416 Mil as of Mar. 2026. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 80/100 and a GF Value™ of ₹102.83 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Zim Laboratories's Long-Term Debt for the quarter that ended in Mar. 2026 was ₹416 Mil.

Zim Laboratories's quarterly Long-Term Debt declined from Sep. 2025 (₹467 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹416 Mil).

Zim Laboratories's annual Long-Term Debt increased from Mar. 2024 (₹356 Mil) to Mar. 2025 (₹403 Mil) and increased from Mar. 2025 (₹403 Mil) to Mar. 2026 (₹416 Mil).

Zim Laboratories  (NSE:ZIMLAB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Zim Laboratories Long-Term Debt Related Terms

Zim Laboratories Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Zim Laboratories's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zim Laboratories Long-Term Debt Chart

Zim Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 189.23 246.25 356.01 403.01 415.88

Zim Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 403.01 0.00 467.24 0.00 415.88
NSE:ZIMLAB
80GF Score
Zim Laboratories Ltd NSE:ZIMLAB
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹416 Mil mean?
Zim Laboratories (NSE:ZIMLAB) has a Long-Term Debt of ₹416 Mil as of Mar. 2026.
Is Zim Laboratories' Long-Term Debt too high?
Zim Laboratories' current Long-Term Debt is ₹416 Mil. Overall, Zim Laboratories has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' Long-Term Debt compare to ZTS and UTHR?
Zim Laboratories' Long-Term Debt of ₹416 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Zim Laboratories's current Long-Term Debt is ₹416 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹102.83, compared to a current price of ₹122.50 — trading 19.1% above its estimated fair value. The current Long-Term Debt is ₹416 Mil. Zim Laboratories' overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current Long-Term Debt is ₹416 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued. The current stock price of ₹122.50 is trading 19.1% above its estimated GF Value™ of ₹102.83. GuruFocus considers Zim Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:ZIMLAB:

  • Long-Term Debt: ₹416 Mil
  • GF Value™: ₹102.83 vs. price of ₹122.50 (19.1% above fair value)
  • GF Score™: 80/100 with 8 warning signs

No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zim Laboratories Business Description

Other Exchanges 541400:India
Address Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
80GF Score

Get the complete analysis for NSE:ZIMLAB

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹122.50
Price
₹102.83
GF Value